Cabozantinib S-malate and Nivolumab in Treating Patients With Advanced, Recurrent, or Metastatic Endometrial Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

82

Participants

Timeline

Start Date

April 16, 2018

Primary Completion Date

May 9, 2025

Study Completion Date

July 23, 2026

Conditions
Advanced Endometrial CarcinomaMetastatic Endometrial CarcinomaRecurrent Endometrial CarcinomaStage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
Interventions
PROCEDURE

Biopsy Procedure

Undergo tumor biopsy

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

DRUG

Cabozantinib S-malate

Given PO

PROCEDURE

Computed Tomography

Undergo CT scan

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

BIOLOGICAL

Nivolumab

Given IV

Trial Locations (34)

10016

Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York

15232

University of Pittsburgh Cancer Institute (UPCI), Pittsburgh

19107

Thomas Jefferson University Hospital, Philadelphia

21287

Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore

22908

University of Virginia Cancer Center, Charlottesville

23298

VCU Massey Comprehensive Cancer Center, Richmond

32610

University of Florida Health Science Center - Gainesville, Gainesville

33612

Moffitt Cancer Center, Tampa

43210

Ohio State University Comprehensive Cancer Center, Columbus

53792

University of Wisconsin Carbone Cancer Center - University Hospital, Madison

55905

Mayo Clinic in Rochester, Rochester

60451

UC Comprehensive Cancer Center at Silver Cross, New Lenox

60462

University of Chicago Medicine-Orland Park, Orland Park

60611

Northwestern University, Chicago

60637

University of Chicago Comprehensive Cancer Center, Chicago

63110

Washington University School of Medicine, St Louis

63129

Siteman Cancer Center-South County, St Louis

63136

Siteman Cancer Center at Christian Hospital, St Louis

63141

Siteman Cancer Center at West County Hospital, Creve Coeur

63376

Siteman Cancer Center at Saint Peters Hospital, City of Saint Peters

66205

University of Kansas Clinical Research Center, Fairway

75235

Parkland Memorial Hospital, Dallas

75390

UT Southwestern/Simmons Cancer Center-Dallas, Dallas

84112

Huntsman Cancer Institute/University of Utah, Salt Lake City

85054

Mayo Clinic Hospital in Arizona, Phoenix

85259

Mayo Clinic in Arizona, Scottsdale

90033

Los Angeles General Medical Center, Los Angeles

USC / Norris Comprehensive Cancer Center, Los Angeles

91010

City of Hope Comprehensive Cancer Center, Duarte

92093

UC San Diego Moores Cancer Center, La Jolla

95817

University of California Davis Comprehensive Cancer Center, Sacramento

02215

Dana-Farber Cancer Institute, Boston

08903

Rutgers Cancer Institute of New Jersey, New Brunswick

M5G 2M9

University Health Network-Princess Margaret Hospital, Toronto

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT03367741 - Cabozantinib S-malate and Nivolumab in Treating Patients With Advanced, Recurrent, or Metastatic Endometrial Cancer | Biotech Hunter | Biotech Hunter